Agenus Reports 72% Had No Cancer Remaining at Surgery in Phase 2 Study
Agenus reported early Phase 2 results for the dMMR colon cancer cohort of the NEOASIS study, which evaluated BOT+BAL after six weeks of treatment.
Story updates
11:01:02 AM UTC
SquawkNews
Agenus reported early Phase 2 NEOASIS results: 83% MPR and 72% pCR after six weeks of neoadjuvant botensilimab plus balstilimab in 18 patients with locally advanced dMMR colon cancer.Material DetailsContext by AI AnalystThis is an early but notable efficacy signal in neoadjuvant dMMR colon cancer…